Connect with us

Technology

‘BOTCHED’ TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION® HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES

Published

3 years ago

on

Doctors Attest to Advanced Energy Technology Device’s Transformative Solutions to Achieve Desired Results in Patients

CLEARWATER, Fla. , Sept. 13, 2022 /PRNewswire/ — Apyx Medical Corporation (NASDAQ: APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the release of a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. 

Leading plastic surgeons across the country are sharing the transformative results they’ve achieved using Renuvion, a proprietary helium plasma and radiofrequency technology, on patients for cosmetic procedures in their practices.

In a video featuring celebrity plastic surgeon and co-host of the hit television series, ‘Botched’  Dr. Paul Nassif, New York City facial surgeon Dr. Tabasum Mir, Beverly Hills plastic and reconstructive surgeon Dr. Leif Rogers and board certified plastic surgeon Dr. Gregory Buford of Denver, CO, doctors reveal the unmatched benefits of using Renuvion technology in their cosmetic/aesthetic procedures.

In the video Dr. Nassif discloses that his practice uses the device four-to-five times a week in cosmetic procedures. Dr. Mir states that she gets impressive tissue contraction in areas she previously was only able to achieve through surgery, while Dr. Rogers testifies that he has tried every device on the market, and now only uses Renuvion for his procedures because it’s far superior to those other devices. Finally, Dr. Buford declares he’d stake his reputation on the safety and effectiveness of Renuvion.

Watch the video here:
Renuvion Review | Top Plastic Surgeons Talk Cutting-Edge Technology – YouTube

 

Renuvion is the only product that is FDA-cleared to improve the appearance of lax (loose) skin on the neck and submental region (chin). It was also recently cleared for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II or III. These clearances highlight the safety and efficacy of the Renuvion technology.

To date, hundreds of physicians across the U.S. use Renuvion in their practices. For a list, by state, of physicians using the device visit: https://renuvionfinder.com.

For additional information visit Renuvion.com.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision while minimizing unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, any statements regarding the potential impact of the COVID-19 pandemic and the actions by governments, businesses and individuals in response to the situation; projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration, supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the U.S. Food and Drug Administration and other governmental and regulatory bodies, both domestically and internationally; the impact of the recent FDA Safety Communication on our business and operations; factors relating to the effects of the COVID-19 pandemic; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Media Contact:

Jane Sparango
Coterie Media on behalf of Apyx Medical Corporation
jane@coteriemedia.com
310-339-1214

Investor Relations Contact:

ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/botched-tv-star-dr-paul-nassif-among-top-us-plastic-surgeons-using-renuvion-helium-plasma-technology-in-cosmetic-procedures-301622598.html

SOURCE Renuvion

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Gamehaus Holdings Inc. to Announce Interim Financial Results for the First Nine Months of Fiscal 2025 on May 19, 2025

Published

48 minutes ago

on

May 15, 2025

By

SHANGHAI, May 15, 2025 /PRNewswire/ — Gamehaus Holdings Inc. (“Gamehaus” or the “Company”) (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced that it will release its unaudited financial results for the first nine months of fiscal year 2025 ended March 31, 2025, before the U.S. market opens on May 19, 2025.

The management team of Gamehaus will host a conference call at 08:00 A.M. Eastern Time on Monday, May 19, 2025 (08:00 P.M. Beijing/Hong Kong time on the same day) to discuss the financial results. In advance of the conference call, all participants must use the following link to complete the online registration process. Upon registering, each participant will receive access details for this conference including a conference passcode, a unique PIN number (personal access code), dial-in numbers, and an e-mail with detailed instructions to join the conference call.

Participant Online Registration: https://dpregister.com/sreg/10199786/ff24367338

A live and archived webcast of the conference call will be available on the Company’s Investor Relations website at https://ir.gamehaus.com/.

About Gamehaus

Gamehaus Holdings Inc. is a technology-driven mobile game publisher dedicated to nurturing partnerships with small- and medium-sized game developers to amplify their success. “You make successful games. We make games successful” is the company’s mantra, encapsulating its commitment to transforming potential into prosperity through data-driven monetization support and optimizing game publishing solutions. For more information, please visit https://ir.gamehaus.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s most recent filings with the U.S. Securities and Exchange Commission.

Investor Relations Contact
Gamehaus Holdings Inc.
Investor Relations Team
Email: IR@Gamehaus.com 

The Blueshirt Group
Mr. Jack Wang
Email: Gamehaus@TheBlueshirtGroup.co 

View original content:https://www.prnewswire.com/news-releases/gamehaus-holdings-inc-to-announce-interim-financial-results-for-the-first-nine-months-of-fiscal-2025-on-may-19-2025-302455120.html

SOURCE Gamehaus Holdings Inc.

Continue Reading

Technology

Bridge to Life Announces Abstract Presentations at The 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore, May 28-31, 2025

Published

48 minutes ago

on

May 15, 2025

By

Abstracts to highlight hypothermic oxygenated perfusion (HOPE) in liver transplants, including pediatric patients

CHICAGO, May 15, 2025 /PRNewswire/ — Bridge to Life™ Ltd., a leader in organ preservation solutions and perfusion technology, today announced the presentation of nine accepted abstracts, including two late-breakers, at the 2025 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Singapore, from May 28-31, 2025.

Abstracts to be presented:

Late Breaker: Impact of Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: A Donor Age-Stratified Analysis, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Late Breaker: Machine Perfusion in Liver Transplantation: A Game Changer for Middle-Volume Centers?, Marco Maria Pascale, Francesco Frongillo, Giorgia Selvaggi, Giuseppe Bianco, Anna Caltabellotta, Erida Nure, Salvatore Agnes, Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy

Use of HOPE Machine Perfusion for Transplantation in Unusual Scenarios – A Case Report, Alba Bueno, Chris Neophytou, George Clarke, Keith Roberts, Khalid Sharif, Rebeca S. Mateos, Hector Vilca-Melendez, Liver Units, Birmingham Children’s Hospital and Queen Elizabeth Hospital, Birmingham, United Kingdom

Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: Preliminary Results, Ane Andrés, María Velayos, Javier Serradilla Rodríguez, Alba Sánchez-Galán, José Luis Encinas, Paula Burgos, Iñigo Velasco, Jorge Utanda, Esteban Frauca y Francisco Hernandez-Oliveros, Hospital Universitario La Paz, Madrid, Spain

HOPE for Hepatocellular Carcinoma – Recurrence Analysis in Patients Transplanted with Grafts Submitted to Hypothermic Oxygenated Perfusion, Maria João Amaral; Mariana Duque; Júlio Constantino; Pedro Oliveira; João Simões; Ricardo Martins; António Pinho; Emanuel Furtado; José Guilherme Tralhão; Dulce Diogo, Coimbra University Hospital Centre, Coimbra, Portugal

The Impact of HOPE on Liver Transplantation for ACLF and ALF: A Promising Perspective, Pedro Pinto, Mariana Lobo, Andreia Matos, Pedro Oliveira, Dulce Diogo, José Tralhão; Coimbra University Hospital Centre, Coimbra, Portugal

Results of Implementation of Hypothermic Oxygenated Perfusion (HOPE) for Human Liver Grafts before transplantation in a Tertiary Hospital, Andrea González De Godos, Francisco Javier Tejero Pintor, Martín Bailón Cuadrado, José Carlos Sarmentero Prieto, Pilar Pinto Fuentes, Enrique Asensio Diaz, Paloma Lourdes Rodríguez Vielba, Fernando Labarga Rodríguez, David Pacheco Sánchez, Hospital Universitario Rio Hortega, Valladolid, Spain

HOPE for combined Heart and Liver Transplant, Mireia Caralt, José Andrés Molino, Jesús Quintero, Núria Montferrer, Joan Balcells, Cristina Padrós, Maria Margaret Mercadal, Raul Feline Abella,Ferran Gran, Ernest Hidalgo, Hospital Universitari Vall d’Hebron, Barcelona, Spain

HOPE for the hopeless grafts. Experience from a single center, Mireia Caralt, Laura Vidal, Sandra Torres, José Andrés Molino, Marta Martos, Piero Alberti, Cristina Dopazo, Concepción Gómez, Itxarone Bilbao, Ramon Charco, Ernest Hidalgo, , Hospital Universitari Vall d’Hebron, Barcelona, Spain

In addition to the abstract presentations, Bridge to Life will also be participating in the Hands-On Liver Machine Perfusion Workshop taking place on May 28, 2025.  Separate registration is required: 5th ILTS Hands-on Liver Machine Perfusion Workshop – ILTS Congress 2025. 

Bridge to Life will also be sponsoring a symposium on May 29 at 3:00 pm SST (UTC+8) on “Expanding the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region”.  Speakers include Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from Cleveland Clinic, Ohio and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital, Birmingham.

About Bridge to Life Ltd

Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US.

Logo – https://mma.prnewswire.com/media/2085277/Bridge_to_Life_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bridge-to-life-announces-abstract-presentations-at-the-2025-international-congress-of-the-international-liver-transplantation-society-ilts-in-singapore-may-28-31-2025-302455913.html

Continue Reading

Technology

Athean Launches with New AI-Powered Sales Platform to Supercharge Prospecting

Published

48 minutes ago

on

May 15, 2025

By

SAN FRANCISCO, May 15, 2025 /PRNewswire/ — Athean, a new AI-driven prospecting and engagement platform, launches today to transform how sales teams win deals. Designed to eliminate tool overload and data silos, Athean centralizes the entire sales ecosystem into one intelligent platform. By streamlining workflows and surfacing actionable insights, Athean supercharges prospecting, enabling teams to easily find and meaningfully engage with high-quality prospects.

“Sales reps are inundated with countless tools for prospecting, valuable data is siloed, and time is lost in the endless switching between platforms,” said John Kim, Co-founder and CEO of Athean. “We created Athean to fill a critical void in the sales technology marketplace – a tool thoughtfully designed to help sales teams deploy their skills more effectively and close better deals faster.”

Athean unifies sales data and tools that reps use daily – from CRMs and prospect databases to communication history – into a single platform, and its AI models arm reps with actionable insights into their accounts. Sales engagement, including calls, emails, and sequences, can also be managed directly in Athean. This seamless access to information enables teams to spend less time gathering data and more time connecting with potential customers.

“Athean isn’t just another prospecting tool; it’s a precise, powerful solution created with the explicit goal of helping individuals master the sales process,” said Kim. “Our intelligent platform provides salespeople with detailed, prioritized insights into their prospect pipeline – who to contact, when, and why – so that they can spend their time on what actually moves deals forward: building relationships.”

Key benefits highlighted in early customer experiences include:

Context: With deep insights into prospects, Athean shines a light on the contacts and context sales teams need to connect meaningfully and efficiently with the right prospects, at the right time.Clarity: Simplified, impactful data presentation integrates seamlessly with your existing tech stack which means less tools and fewer tabs, eliminating the distraction and chaos of prospecting to give sales reps clarity and focus.Connection: We estimate Athean can free up as much as two hours every day, allowing reps to do what they do best: building genuine, lasting relationships.

Athean was originally designed at Silicon Valley security company, Verkada, to be used by their 1,000+ person sales team. Athean will operate as an independent venture of Verkada and is now publicly available to sales teams eager to elevate their prospecting efforts. Learn more at Athean.com.

About Athean
Athean is an AI-driven prospecting and engagement platform that unifies customer and prospect data, communications history, and market signals to transform how sales teams win deals. Athean’s AI-powered tools eliminate tab-switching and manual validation, helping sales reps to identify high potential accounts, surface relevant intel and engage with enriched prospect data – arming your team with the contextual knowledge that builds instant credibility. The result: better conversations, more qualified opportunities, and ultimately, more closed revenue. For more information, please visit www.athean.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/athean-launches-with-new-ai-powered-sales-platform-to-supercharge-prospecting-302456043.html

SOURCE Athean

Continue Reading

Trending